Vanguard Portfolio Management
PLRX icon

Vanguard Portfolio Management’s Pliant Therapeutics PLRX Stock Holding History

Vanguard Portfolio Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Sell
153,712
-98
-0.1% -$119 ﹤0.01% 3118
2026
Q1 		$194K Buy
+153,810
New +$194K ﹤0.01% 3049

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Portfolio Management's PLRX Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Pliant Therapeutics (PLRX) stake by 0.06% in Q2 2026, selling an estimated $119 and leaving 153,712 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #3118.

Vanguard Portfolio Management first reported a position in PLRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $194K in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Vanguard Portfolio Management held 153,712 shares of Pliant Therapeutics worth $175K as of Q2 2026.
  • Vanguard Portfolio Management sold 98 Pliant Therapeutics shares in Q2 2026, an estimated $119.
  • Pliant Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3118 holding.
  • Vanguard Portfolio Management first reported a position in Pliant Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Pliant Therapeutics position peaked at $194K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.